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OBJECTIVES In this study, we investigated the crosstalk of endothelin-1 (ET-1) and platelet-derived
growth factor (PDGF) in coronary artery smooth muscle cell (SMC) proliferation in the rat
cardiac allograft model.
BACKGROUND Previous studies have suggested an independent role of ET-1 and PDGF in the development
of cardiac allograft arteriosclerosis (i.e., chronic rejection).
METHODS Heterotopic heart transplantations were performed from Dark Agouti to Wistar Furth rats.
Grafts were harvested after five days in an acute rejection model and after 60 days in a chronic
rejection model. In the in vitro part of the study, SMC proliferation and migration were
quantitated, as well as messenger ribonucleic acid (mRNA) levels of ET-1 and PDGF ligands
and receptors after growth factor stimulation.
RESULTS Acute rejection induced both ET-1 receptors in the arterial wall. On linear regression analysis
of chronically rejecting cardiac allografts, a strong correlation between intimal thickening
and immunoreactivity of ET-1 and ET receptors A and B (ETA and ETB) in the arterial
walls was observed. Treatment with Bosentan, a mixed ET-1 receptor antagonist,
significantly reduced the incidence and intensity of arteriosclerotic lesions in rat cardiac
allografts, as well as total intragraft ETA and ETB mRNA expression and intimal cell
ET-1 and receptor immunoreactivity. This was associated with significantly reduced
intragraft PDGF beta-receptor (PDGF-Rbeta) mRNA expression. In contrast, CGP
53716, a protein tyrosine kinase inhibitor selective for the PDGF receptor, did not reduce
intragraft ET-1, ETA or ETB mRNA expression. In rat coronary artery SMC cultures,
ET-1 stimulation significantly upregulated PDGF-Ralpha and -Rbeta mRNA expression
and augmented PDGF-BB–mediated SMC proliferation as well as PDGF-AB– and
PDGF-BB–mediated SMC migration.
CONCLUSIONS Our results suggest that the ET-1/PDGF-Rbeta/PDGF-BB axis may operate in SMC
migration and proliferation in cardiac allograft arteriosclerosis, thus explaining the marked
beneficial effects of blocking the signaling downstream of ET-1 receptors. (J Am Coll
Cardiol 2002;39:710–7) © 2002 by the American College of Cardiology
Active endothelin-1 (ET-1) is a 21-amino acid peptide
proteolytically generated from its precursor preproET (1).
Endothelin-1 is the most potent known vasoconstrictor
released from endothelial cells (ECs) to act on the under-
lying vascular smooth muscle cells (SMCs) (2,3). The effects
of ET-1 are mediated through two G-protein–coupled
receptors—the ET receptors A and B (ETA and ETB).
Ligand binding results in activation of intracellular phos-
pholipase C and release of calcium from sarcoplasmic
reticulum, leading to its biologic responses (1). Both ETA
and ETB subtypes are expressed by vascular SMCs and
mediate vasoconstriction (4). In ECs, ETB is the predom-
inating subtype and mediates vasodilation through release of
vasoactive factors such as nitric oxide (5).
In addition to its vasoactive functions, ET-1 acts as a
growth factor for SMCs (6). The proinflammatory cyto-
kines interleukin-1-beta (IL-1-beta) and tumor necrosis
factor-alpha (TNF-alpha) upregulate ET-1 mRNA levels
in ECs (7). In vascular SMCs, platelet-derived growth
factor-AA (PDGF-AA) induces production of ET-1 at
protein and mRNA levels (8,9). Through these vasoactive
and mitogenic effects, activation of ET-1 expression is
connected to many vascular disorders (10,11).
PDGF-BB is the most potent mitogen for SMCs in vitro
and is expressed in macrophages of intimal lesions of
ordinary atherosclerosis (12,13). PDGF-AA is a weak
mitogen for SMC proliferation in vitro, but our previous
results suggest that it plays a major role in the development
of intimal lesions in a macrophage-derived cytokine micro-
environment in cardiac allograft arteriosclerosis (14,15).
Recent studies indicate that ET-1 may also regulate SMC
proliferation in arteriosclerosis, but the role of ET-1 as a
direct SMC mitogen remains controversial (6,16). In this
study, we investigated the interaction between ET-1 and
PDGF in rat coronary artery SMC cultures in vitro and in
the cardiac allograft model in vivo.
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METHODS
Heterotopic heart transplantation. Inbred Dark Agouti
(AG-B4, RT1a) and Wistar Furth (AG-B2, RT1u) rat
strains (weighing 200 to 300 g) (Laboratory Animal Center,
University of Helsinki, Helsinki, Finland) were used for
heterotopic heart transplantations, as described (17). In the
acute rejection model, the recipients were not immunosup-
pressed, and the grafts were removed five days after trans-
plantation. In the chronic rejection model, the allografts
were treated with Bosentan, 100 mg/kg body weight per
day, or vehicle by orogastric tube and cyclosporin A (CsA),
2 mg/kg per day subcutaneously for the first week and
1 mg/kg per day thereafter, and the grafts were removed 60
days after transplantation. To analyze the correlation be-
tween the development of intimal thickening and ET-1
ligand and receptor expression, the recipients were given
CsA at a dose of either 1.0 mg/kg per day, 1.5 mg/kg per
day or 2 mg/kg per day for two weeks, followed by one week
of CsA at 1 mg/kg per day. We have previously demon-
strated an inverse correlation between CsA levels and
intimal thickening (18).
To investigate the effects of PDGF inhibition on ET-1
ligand and receptors in the chronic rejection model, the rats
received CGP 53716, 50 mg/kg per day intraperitoneally by
a single injection starting 24 h before transplantation. As
CGP 53716 interacts with CsA metabolism, CsA was
administrated according to blood trough levels (14). The
administration of CsA, 2 mg/kg for the first week, followed
by 1.5 mg/kg, yielded blood trough levels in vehicle-treated
rats that matched those in rats treated with CsA, 1 mg/kg
per day, and CGP 53716 (14).
Drug regimens. Cyclosporin A (Sandimmune; Novartis,
Basel, Switzerland) was dissolved in Intralipid, 200 mg/ml
(KabiVitrum, Stockholm, Sweden) to a final concentration
of 1 mg/ml. Whole blood CsA 24-h trough levels were
determined once a week using radioimmunoassay (Sandim-
mune kit; Novartis). Bosentan (Ro 47-0203/029), an orally
active nonpeptide ET antagonist (kindly provided by Dr.
M. Clozel, Actelion Ltd., Allschwil, Switzerland) (19), was
suspended in 5% gummi arabicum to a concentration of 25
mg/ml. CGP 53716, a protein tyrosine kinase inhibitor
selective for the PDGF receptor (Novartis), was dissolved in
dimethyl sulfoxide to a concentration of 200 mg/kg, diluted
1:20 with 1% Tween in 0.9% NaCl, and sonicated.
Histologic findings. The grafts embedded in paraffin were
examined histologically after sectioning and staining with
hematoxylin-eosin and resorcin-fuchsin (internal elastic
lamina). The changes in intimal thickness of each vessel
were scored from 0 to 4, as previously described (14). As a
final score for intimal thickening, the mean score of epicar-
dial arteries and intramyocardial arterioles per cross section
was given.
Immunostaining. Immunohistochemical analyses were
performed using the ABC method (Vectastain Elite ABC
kit, Vector Laboratories, Burlingame, California). The fol-
lowing polyclonal antibodies were applied: rabbit anti–ET-1
(porcine/human) serum (dilution of 1:50; Peninsula Labo-
ratories Inc., San Carlos, California), sheep anti-rat ETA
and sheep anti-rat ETB (dilution of 16 g/ml; U.S. Bio-
logical, Swampscott, Massachusetts). Immunoreactivity was
scored from 0 to 3, as previously described (14). Specificity
control stainings included omission of primary antibody and
staining with the same immunoglobulin concentration of
species- and isotype-matched antibodies. None of these
control stains showed any immunoreactivity.
Cell cultures. A rat coronary artery SMC line (kindly
provided by Dr. D. Leszczynski, Finnish Center for Radi-
ation and Nuclear Safety, Helsinki, Finland), was cultured
in 10% fetal bovine serum (FBS) Dulbecco’s Modified
Eagle Medium (DMEM), supplemented with 10 mmol/l
HEPES, 100 IU/ml penicillin, 100 g/ml streptomycin and
1% glutamine (GIBCO BRL, Rockville, Maryland). For
proliferation analysis, the cells were trypsinized and seeded
on microwells in culture medium containing 10% FBS at a
concentration of 25,000 cells/ml and allowed to adhere for
24 h. After starvation in serum-free medium for 72 h,
quiescent cells were either incubated with 20 ng/ml of
PDGF-AA, -AB or -BB (Upstate Biotechnology Inc.,
Waltham, Massachusetts) for 24 h or pre-incubated with
10 ng/ml of ET-1 (Peninsula Laboratories Inc.) in 0.5%
FBS DMEM, supplemented with 0.1% bovine serum albu-
min for 24 h and then with PDGF ligands for another 24 h.
3H-TdR incorporation (1 Ci/ml) was measured during the
last 24 h of incubation. For migration analysis, Transwell
culture chambers (Costar, Acton, Massachusetts) were
coated with collagen (Upstate Biotechnology Inc.), and
50,000 cells were seeded in the upper chamber. After 2 h,
ET-1, PDGF-AA, PDGF-AB and PDGF-BB were added
to the lower chamber and incubated for 24 h. Filters were
fixed in methanol, stained with Mayer’s hemalum and
removed. Migrated cells on the lower side of the filter were
quantitated by counting cross-sectional fields with a light
microscope using400 magnification. For mRNA analysis,
the cells were starved for 72 h in 0.5% FBS DMEM,
supplemented with 0.1% BSA. Quiescent cells were chal-
lenged with 20 ng/ml of ET-1 in a serum-free medium,
Abbreviations and Acronyms
CsA  cyclosporin A
DMEM  Dulbecco’s Modified Eagle Medium
EC  endothelial cell
ET  endothelin
FBS  fetal bovine serum
IL  interleukin
mRNA  messenger ribonucleic acid
PDGF  platelet-derived growth factor
RT-PCR  reverse transcription polymerase chain
reaction
SMC  smooth muscle cell
TNF  tumor necrosis factor
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washed with phosphate-buffered saline (PBS) and harvested
in buffer at 4 h.
Reverse transcription polymerase chain reaction (RT-
PCR). Relative preproET-1, ETA, ETB and PDGF-A,
PDGF-B, PDGF-alpha and PDGF-beta mRNA transcript
levels were measured with RT-PCR after normalization
against levels of the reference gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Total RNA was
extracted from fresh heart tissue samples and cell culture
samples, as described (20,21). After deoxyribonuclease
treatment, the total RNA yields were estimated by spectro-
photometry and confirmed by 1% agarose/Tris-borate-
EDTA gel electrophoresis. Reverse transcription PCR was
performed as described (22). The sense and antisense





for ET-RA (M60786): 5-GAAGTCGTCCGTG-
GGCATCA-3 and 5-CTGTGCTGCTCGCCCTT-
GTA-3; for ET-RB X57764: 5-TTACAAGACAGCC-
AAAGACT-3 and 5-CACGATGAGGACAAT-
GAGAT-3; for PDGF-A (L06238): 5-AGAAGTAT-
TGAGGAAGCCATTCC-3 and 5-TCACCTGGACC-




3 and 5-CACACTGAAGGTTCCGTTGAAG-3; and
for PDGF-beta (Z14119): 5-TCGTCCTCAAC-
ATTTCGAGC-3 and 5-TCATAGGGTACATGTA-
GGGGGAT-3. Gene transcript levels for a single gene were
amplified simultaneously, and each PCR analysis was com-
pleted in triplicate. For each experiment, negative control
studies were performed using water instead of complementary
deoxyribonucleic acid (cDNA) or omitting reverse transcrip-
tase during cDNA synthesis. None of these control studies
showed positive signals. The mean values of three determina-
tions were used for the final analysis, and the normalized gene
mRNA transcript levels were derived by dividing the mean
value of the gene mRNA by the mean value of GAPDH for
each sample. The results are given as optical density values,
with the control group given the numeric value of 1.
Statistical analyses. All data are given as the mean value
SEM. The Mann-Whitney U test, z-corrected for ties
(Statview program, version 4.1; Abacus Concepts, Berkeley,
California), was used to evaluate the differences between
two groups. For multiple comparisons, the Kruskal-Wallis
and Dunn tests were applied (Medstat, Astra Group A/S).
In addition, linear regression analysis was applied to evalu-
ate the possible relationship of growth factor ligand and
receptor expression to intimal thickening. A p value 0.05
was regarded as statistically significant.
RESULTS
Bosentan reduces arteriosclerotic lesion formation in
cardiac allografts. The mean numbers of arteries and
arterioles in the cardiac cross sections analyzed were 45  5
in allografts of vehicle-treated rats and 53  7 in allografts
of bosentan-treated rats. In cardiac allografts of vehicle-
treated rats, 90  4% of vessels were affected by intimal
thickening, and the mean grade of intimal thickening was
1.8  0.3. Treatment with bosentan significantly reduced
the amount of affected vessels to 53  7% (p  0.01) and
the mean grade of intimal thickening to 0.8  0.2 (p 
0.01) (Fig. 1).
Alloimmune response induces ET-1 receptor activation
in the arterial wall, which may be inhibited by bosentan.
PROTEIN EXPRESSION. In nontransplanted DA rat hearts,
mild to moderate ET-1 expression was localized to media
cells of arteries and cardiomyocytes. In syngeneic grafts,
ET-1 expression did not differ from that of nontransplanted
hearts. Acute rejection induced mild ET-1 immunoreactiv-
ity in the interstitial mononuclear inflammatory cells (Table
1). In syngeneic grafts 60 days after transplantation, ET-1
expression was nonexistent in the media cells of arteries and
moderate in cardiomyocytes. Expression of ET-1 was in-
creased in the intima and media cells of arteries in chroni-
cally rejecting allografts, compared with syngeneic grafts.
Treatment with bosentan significantly reduced ET-1 ex-
pression in the intima and media cells, compared with
vehicle treatment (Table 2).
Mild to moderate ETA immunoreactivity was recorded in
the media cells and cardiomyocytes of normal hearts. In
syngeneic grafts, moderate ETA expression was detectable
in cardiomyocytes. Expression of ETA was significantly
upregulated in the media cells of arteries and in the
interstitial mononuclear inflammatory cells in the acute
rejection model, compared with syngeneic grafts (Table 1).
In syngeneic grafts at 60 days, mild to moderate ETA
expression was detectable in the media cells and cardiomy-
ocytes. In chronically rejecting allografts, ETA immunore-
activity was significantly increased in the intima and media
cells of the arterial wall, compared with syngeneic grafts. In
bosentan-treated allografts, there was a reduction in ETA
immunoreactivity in intimal cells, compared with vehicle-
treated allografts (Table 2).
In nontransplanted DA rat hearts, mild to moderate ETB
expression was localized to endothelial and media cells and
cardiomyocytes. In syngeneic grafts, ETB expression was
undetectable in ECs but was otherwise similar to that seen
in nontransplanted DA rat hearts. During acute rejection,
ETB immunoreactivity was upregulated in the media cells of
allograft arteries, compared with syngeneic graft arteries
(Table 1). In syngeneic grafts at 60 days, ETB immunore-
activity was not detectable in ECs and was mild in the
media cells of arteries. In chronically rejecting allografts, the
expression of ETB was increased in the intima and media
cells of arteries. In bosentan-treated allografts, a clear
712 Sihvola et al. JACC Vol. 39, No. 4, 2002
Crosstalk of ET-1 and PDGF in Chronic Rejection February 20, 2002:710–7
reduction in ETB expression was recorded, compared with
vehicle-treated allografts (Table 2).
EXPRESSION OF mRNA IN THE ACUTE REJECTION MOD-
EL. In syngeneic and allogeneic grafts, there was a 2.9 
0.4- and 3.6  0.1-fold increase, respectively, in optical
density in total intragraft preproET-1 mRNA expression,
compared with normal hearts (p  0.01). At the receptor
level, no difference in total intragraft mRNA expression was
observed between the groups.
EXPRESSION OF mRNA IN THE CHRONIC REJECTION MOD-
EL. Sixty days after transplantation, no significant difference
in preproET-1 mRNA expression was observed between
syngeneic and allogeneic hearts. However, expression of
both ETA and ETB mRNA was significantly increased
(1.8  0.1- and 1.9  0.2-fold increase in optical density,
respectively) in chronically rejecting allografts as compared
with syngeneic grafts (p  0.05). Bosentan treatment
reduced total intragraft ETA mRNA expression by 39 5%
(p  0.01), compared with vehicle treatment.
Intimal cell ET-1 ligand and receptor immunoreactivity
correlates with arteriosclerotic lesion formation. As
shown in Figure 2, linear regression analysis revealed that
ET-1 immunoreactivity in the intima cells correlated with
the severity of chronic rejection. At the receptor level, the
expression of ETA in the intima cells and that of ETB in the
intima and media cells of arteries correlated with enhanced
intimal thickening.
Endothelin-1 regulates SMC proliferation and migration
downstream of PDGF-beta. There were 2.2  0.2- and
1.6  0.1-fold increases in optical density of PDGF-alpha
and -beta mRNA expression, respectively, in cultured
SMCs stimulated with ET-1, but the mRNA expression of
PDGF-A and -B ligands remained unchanged (p  0.05).
On stimulation with ET-1, PDGF-AA, PDGF-AB and
PDGF-BB alone, there were 1.5-, 2-, 3- and 4-fold
increases, respectively, in SMC 3H-TdR incorporation (Fig.
3). When SMCs were prestimulated with ET-1 for 24 h,
only PDGF-BB, but not PDGF-AA nor -AB, significantly
(p  0.001) upregulated 3H-TdR incorporation in SMCs
(Fig. 3).
Endothelin-1 and PDGF-AA stimulation had no effect
on SMC migration, whereas PDGF-AB and PDGF-BB
stimulation induced a threefold increase in SMC migration.
When SMCs were stimulated with ET-1, PDGF-AB and
PDGF-BB significantly upregulated SMC migration (Fig. 3).
Figure 1. Effect of Bosentan (Ro 47-0203), an ET-1 receptor antagonist, on (A) incidence and (B) mean score of intimal thickness in epicardial arteries
and intramyocardial arterioles of rat cardiac allografts. Allograft recipients were given Bosentan, 100 mg/kg per day (n  9), or vehicle (n  7), and, as
background immunosuppression, CsA, 2 mg/kg per day for the first week and 1 mg/kg per day thereafter. The grafts were removed 60 days after
transplantation. Data are given as the mean value  SEM; data were analyzed by using the Mann-Whitney U test. Grade 0  normal artery with intact
internal elastic lamina; grade 1  10% occlusion of the lumen by arterial intimal thickening and proliferation, disruption of the internal elastic lamina
and the presence of some foam or vacuolated ECs; grade 210% but50% occlusion of the lumen; grade 350% but100% occlusion of the lumen;
and grade 4 100% vessel occlusion of the lumen. Photomicrographs of the coronary arteries of vehicle-treated (C) and Ro 47-0203–treated (D) rat cardiac
allografts. Original magnification 200. Hematoxylin-eosin and resorcin-fuchsin staining for internal elastic lamina.
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Bosentan reduces intragraft PDGF-beta mRNA expres-
sion during chronic rejection. In chronically rejecting
cardiac allografts, bosentan treatment decreased the mRNA
expression of PDGF-beta by 31  4% (p  0.05), whereas
the mRNA expression of PDGF-A, -B and -alpha re-
mained unchanged 60 days after transplantation.
CGP 53716 does not reduce ET-1 ligand and receptor
mRNA expression. Our previous observations show that
treatment with CGP 53716 significantly reduces intimal
thickening from 1.2  0.1 to 0.6  0.1, compared with
vehicle treatment (14). In chronically rejecting cardiac
allografts, treatment with CGP 53716 did not reduce
intragraft ET-1, ETA or ETB mRNA expression (data not
shown).
DISCUSSION
The results of the present study demonstrate that during the
alloimmune response, ET-1 receptor activation occurs in
arterial SMCs. In acutely rejecting cardiac allografts, a
significant induction of ET-1 in interstitial mononuclear
inflammatory cells and ETA and ETB in the media cells of
coronary arteries was observed, indicating possible activa-
tion and functional change of SMCs early after transplan-
tation (23). On linear regression analysis of chronically
rejecting cardiac allografts, a strong correlation between
intimal thickening and immunoreactivity of ET-1, ETA
and ETB in intimal cells was observed. Treatment with
bosentan, a mixed ET-1 receptor antagonist, significantly
reduced the incidence and intensity of arteriosclerotic le-
sions in rat cardiac allografts, decreased total intragraft ETA
and ETB mRNA expression and intimal cell ET-1, ETA
and ETB immunoreactivity and also reduced PDGF-beta
mRNA expression. These and previous results demonstrate
a possible functional role for ET-1 in the regulation of
intimal thickening in cardiac allograft arteriosclerosis
(10,11,24,25).
Endothelin-1 regulates PDGF receptor expression in
SMCs and augments PDGF-mediated SMC prolifera-
tion and migration. The role of ET-1 as a direct SMC
mitogen, however, has been controversial (6,16). Previous
studies suggest that ET-1 is a weak mitogen for vascular
SMCs, but in the presence of PDGF-BB, its effects are
markedly potentiated (6,26). These effects were shown to be
mediated primarily by ETA and not to be attributable to
overexpression of PDGF receptors and potentiation of
PDGF-induced MAPK activation (26). However, the re-
sults of the present study demonstrate that when rat
coronary artery SMCs are challenged with ET-1, mRNA
expression of PDGF-Ralpha and -Rbeta is significantly
upregulated, whereas the expression of PDGF ligands
remains unchanged. On stimulation with ET-1, a weak
mitogenic response comparable to that of PDGF-AA was
observed in cultured rat coronary artery SMCs. Prestimu-
lation with ET-1 showed a significant co-mitogenic effect
with PDGF-BB, whereas prestimulation did not signifi-
cantly alter the responses to PDGF-AA or -AB.
Endothelin-1 did not enhance SMC migration alone, but
the effects of PDGF-AB and -BB were potentiated with
Table 1. Endothelin-1 Ligand and Receptor Protein Expression




Normal DA rat hearts 0 0 1.3  0.2
DA 3 DA grafts 0 0 0
DA 3 WF grafts 0 0.1  0.1 0.2  0.2
Intimal cells
Normal DA rat heart 0 0 0
DA 3 DA grafts 0 0 0
DA 3 WF grafts 0 0 0.2  0.2
Medial cells
Normal DA rat heart 0.5  0.3 0.5  0.0 1.0  0.0
DA 3 DA grafts 0.8  0.5 0 0.9  0.4
DA 3 WF grafts 0.8  0.3 1.6  0.3* 1.8  0.3*
Cardiomyocytes
Normal DA rat heart 1.3  0.2 1.5  0.0 1.5  0.0
DA 3 DA grafts 1.5  0.0 1.3  0.1 1.4  0.1
DA 3 WF grafts 1.3  0.3 1.3  0.1 1.2  0.2
Interstitial mononuclear cells
Normal DA rat heart 0 0 0
DA 3 DA grafts 0 0 0
DA 3 WF grafts 0.8  0.3* 0.7  0.3* 0
*p  0.05 when DA3WF grafts were compared with DA3 DA grafts or †when
DA3DA grafts were compared with normal DA rats hearts, by the Mann-Whitney
U test. The number of grafts analyzed was 3, 4 and 6 in the normal DA rat hearts.
DA3DA and DA3WF grafts, respectively. Immunohistochemistry findings were
scored from 0 to 3. Data are presented as the mean value  SEM.
DA  Dark Agouti; ET  endothelin; WF  Wistar Furth.
Table 2. Effect of Bosentan (Ro 47-0203) on Endothelin-2
Ligand and Receptor Protein Expression in Cardiac Allografts
60 Days After Transplantation
ET-1 ETA ETB
Arterial endothelial cells
DA 3 DA grafts 0 0 0
DA 3 WF  vehicle 0.2  0.2 0.1  0.1 0
DA 3 WF  Ro 47-0203 0.1  0.1 0 0
Intimal cells
DA 3 DA grafts 0 0 0
DA 3 WF  vehicle 1.4  0.4* 1.3  0.5 1.7  0.3*
DA 3 WF  Ro 47-0203 0.1  0.1† 0.4  0.3 0.3  0.3†
Medial cells
DA 3 DA grafts 0.1  0.1 0.5  0.4 1.1  0.5
DA 3 WF  vehicle 2.1  0.3* 1.9  0.3* 2.2  0.2
DA 3 WF  Ro 47-0203 1.3  0.3† 1.8  0.2 1.8  0.3
Cardiomyocytes
DA 3 DA grafts 1.6  0.1 1.5  0.0 1.3  0.1
DA 3 WF  vehicle 1.0  0.1 1.1  0.2 0.7  0.2
DA 3 WF  Ro 47-0203 0.8  0.2 1.3  0.2 0.8  0.2
Interstitial mononuclear cells
DA 3 DA grafts 0 0.1  0.1 0
DA 3 WF  vehicle 0.3  0.1 0.2  0.1 0.1  0.1
DA 3 WF  Ro 47-0203 0.1  0.1 0.1  0.1 0.9  0.3
*p  0.05 when the vehicle group was compared to DA 3 DA grafts by the
Mann-Whitney U test or †when the Ro 47-0203 treatment group was compared with
vehicle group. The number of grafts analyzed was 4, 7 and 8 in the DA 3 DA,
DA 3 WF  vehicle, DA 3 WF  Ro 47-0203 groups, respectively. Immuno-
histochemistry findings were scored from 0 to 3. Data are presented as the mean 
SEM.
Abbreviations as in Table 1.
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ET-1. When evaluating the results of the SMC prolifera-
tion and migration studies, the concept of the isoform-
specific association of both PDGF receptor subunits is key:
binding of PDGF to its receptor requires dimerization and
is restricted to a ligand-specific association of the ligand
subunits (27). For example, PDGF-AA binds only to the
alpha-alpha receptor homodimer, AB to alpha-alpha and
alpha-beta receptors and BB to all possible receptor dimers
(alpha-alpha, alpha-beta and beta-beta). However,
PDGF-AB is able to induce beta-beta receptor homodimers
(28) and does not require alpha receptors for functional
binding (29).
Blocking of the ET-1 pathway with Bosentan decreases
PDGF-beta mRNA expression in cardiac allografts. To
test the hypothesis that ET-1 regulates SMC proliferation
by induced PDGF receptor activation in vivo, the effects of
Bosentan treatment on PDGF ligand and receptor mRNA
expression were examined. The results showed that treat-
ment with Bosentan significantly decreased the intragraft
PDGF-Rbeta mRNA expression in cardiac allografts. In
contrast, treatment with the selective PDGF protein recep-
tor tyrosine kinase inhibitor CGP 53716 did not reduce
intragraft preproET-1 mRNA expression. Rather, the
mRNA levels of ETA and ETB were increased during CGP
Figure 2. To analyze the correlation between the development of intimal thickening and ET-1 ligand and receptor expression, allograft recipients were
given CsA at a dose of either 1.0, 1.5 or 2 mg/kg per day for two weeks, followed by one week of CsA at 1 mg/kg per day. The correlation of intimal
thickening with ET-1 (left column), ETA (middle column) and ETB (right column) protein expression in the arterial wall of chronically rejecting
allografts, analyzed by linear regeression analysis. Correlation coefficients (r2) are given. Immunohistochemistry findings were scored from 0 to 3 (0  no
visible staining; 1  few cells with faint staining; 2  moderate intensity with multifocal staining; and 3  intense diffuse staining of the cells).
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53716-treatment. As demonstrated in the in vitro part of
the study, ET-1 itself is not a strong mitogen and does not
stimulate SMC migration, but it augments these functions
through PDGF. Thus, even though ET-1 ligand and
receptor expression remains high during CGP 53716 treat-
ment, the net effect is downregulation of arteriosclerosis, as
the key mediator, and the PDGF activation pathway is
blocked. These in vitro and in vivo results speak for the
priming function of ET-1 in PDGF-mediated signaling,
suggesting intracellular crosstalk between G-protein–
coupled ET receptors and protein tyrosine kinase PDGF
receptors in the development of allograft arteriosclerosis.
The results also explain the clear beneficial effect of ET-1
receptor antagonism, leading to reduced PDGF-Rbeta ex-
pression in cardiac allograft arteriosclerosis, although ET-1,
itself, is a weak mitogen for SMCs.
The ET-1/PDGF-Rbeta/PDGF-BB axis may operate in
heart allograft arteriosclerosis. In vitro studies have
shown that activation of PDGF-Ralpha leads to SMC
proliferation but inhibits migration, whereas activation of
PDGF-Rbeta stimulates both the proliferative and migra-
tory responses of SMCs (30). Although PDGF-BB is a
potent mitogen for SMCs in vitro, in vivo studies using rat
cardiac allografts have shown that PDGF-AA, -Ralpha and
-Rbeta expression in intimal cells, as well as PDGF-BB
expression only in interstitial mononuclear inflammatory
cells, correlates with intimal thickening (15). Blocking of
signaling downstream of PDGF receptors by CGP 53716
significantly reduced arteriosclerotic lesion formation (14).
When rat coronary SMCs were stimulated with PDGF-AA
or -BB in the presence of IL-1-beta or TNF-alpha, the drug
significantly inhibited only AA-ligand–induced prolifera-
tion. This was explained by the observation that in coronary
artery SMC culture, IL-1-beta and TNF-alpha specifically
upregulated PDGF-Ralpha mRNA expression, whereas the
expression of other PDGF ligands and receptors remained
unchanged (14). Endothelin-1, IL-1-beta and TNF-alpha
can induce the production of ET-1 from ECs (7), although
in our cardiac allograft model, ET-1 immunoreactivity in
arterial ECs was nonexistent, and mononuclear inflamma-
tory cells, most likely activated macrophages, demonstrated
mild ET-1 immunoreactivity. In addition, preproET-1
mRNA expression in SMCs may be induced by PDGF-AA
(8,9). Thus, synthesis of these results implies that ET-1 and
PDGF produced by activated macrophages may regulate
migratory and proliferative SMC responses by PDGF-
Rbeta in intimal lesion development in rat cardiac allograft
arteriosclerosis.
Conclusions. We show here that ET-1 alone is a weak
mitogen for SMCs, but it regulates PDGF receptor expres-
sion in SMCs and augments PDGF-BB–mediated SMC
proliferation as well as PDGF-AB– and PDGF-BB–
mediated SMC migration. The ET-1 receptor antagonist
significantly reduced the incidence and intensity of arterio-
Figure 3. (A) Effects of ET-1 and PDGF on 3H-TdR incorporation into coronary artery SMCs in vitro. After 96- or 72-h serum starvation, quiescent
SMCs were either incubated with ET-1, PDGF-AA, PDGF-BB or PDGF-AB for 48 h, or prestimulated with ET-1 for 24 h; thereafter, PDGF-AA,
-AB or -BB was added to cultures for 48 h, respectively. Incorporation of 3H-TdR (1 Ci/ml) was measured during last 24 h. Six parallel wells were used
for the determinations, and the experiment was repeated twice. (B) Effects of ET-1 and PDGF into coronary artery SMC migration in vitro. The cells were
seeded in porous membranes separating the upper and lower chambers. After 2 h, ET-1, PDGF-AA, PDGF-BB and PDGF-AB were added to the lower
chamber and incubated for 24 h at 37°C. Migrated cells on the lower side of the filter were quantitated by counting the cells on the lower side of the filter.
Three parallel wells were used for the determinations, and the experiment was repeated twice. Data are expressed as the mean value  SEM. NIL  no
treatment.
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sclerotic lesions in rat cardiac allografts, as well as intragraft
PDGF-beta mRNA expression. Our results suggest that the
ET-1/PDGF-Rbeta/PDGF-BB axis may operate in SMC
migration and proliferation in cardiac allograft arterioscle-
rosis and may explain the marked beneficial effects of
blocking the signaling downstream of ET-1 receptors.
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